U.S. Stock Futures Slip as Markets Brace for Big Tech Earnings and Key Data 
Philippines Manufacturing PMI Hits Nine-Month High Despite Weak Confidence Outlook 
Japan Finance Minister Defends PM Takaichi’s Remarks on Weak Yen Benefits 
S&P 500 Rises as AI Stocks and Small Caps Rally on Strong Earnings Outlook 
Trump Announces U.S.–India Trade Deal Cutting Tariffs, Boosting Markets and Energy Ties 
Starmer’s China Visit Highlights Western Balancing Act Amid U.S.-China Rivalry 
UK Employers Plan Moderate Pay Rises as Inflation Pressures Ease but Persist 
IMF Forecasts Global Inflation Decline as Growth Remains Resilient 
Gold, Silver, and Platinum Rally as Precious Metals Recover from Sharp Selloff 
Oil Prices Slide Nearly 3% as U.S.-Iran Talks Ease Geopolitical Tensions 
India Budget 2026: Modi Government Eyes Reforms Amid Global Uncertainty and Fiscal Pressures 
EU Recovery Fund Faces Bottlenecks Despite Driving Digital and Green Projects 
Japan Election Poll Signals Landslide Win for Sanae Takaichi, Raising Fiscal Policy Concerns 
Indian Rupee Strengthens Sharply After U.S.-India Trade Deal Announcement 
Dollar Holds Firm as Strong U.S. Data, Fed Expectations and Global Central Bank Moves Shape Markets 
South Korea Inflation Hits Five-Month Low as CPI Reaches Central Bank Target 
China’s WuXi AppTec has signed an agreement to sell its gene therapy manufacturing arm, WuXi Advanced Therapies, to U.S.-based Altaris LLC, following mounting restrictions on Chinese firms in the United States over national security concerns. The deal also includes Oxford Genetics in the UK.
WuXi AppTec Sells Gene Therapy Unit Amid US Restrictions
The Chinese company WuXi AppTec announced on Tuesday that its subsidiaries have inked a contract with the private equity firm Altaris LLC, which is based in the United States, for the sale of its cell and gene therapy manufacturing unit, WuXi Advanced Therapies, for an amount that has not been disclosed.
Due to worries regarding national security, the corporation, along with other Chinese businesses, has been at the focus of new regulations that have been enacted in the United States with the intention of restricting their businesses in the United States, Investing.com shares.
US Legislation Targets Chinese Companies Over National Security Concerns
In September, the House of Representatives of the United States of America enacted a bill that would bar the federal government from entering into contracts with specified companies and those that do business with those companies.
The laws are intended to protect the personal health and genetic information of Americans from foreign adversaries.
Shift in US Pharma and Biotech Supply Chains
Additionally, they intend to encourage pharmaceutical and biotechnology businesses in the United States to reduce their reliance on China for a variety of activities, including the manufacturing of medicinal ingredients and early research.
The United Kingdom-based operating company of the WuXi ATU business, Oxford Genetics, will be sold to Altaris LLC, according to a statement made by WuXi.
Altaris declined to comment further than the information that was provided, while WuXi AppTec did not react to a request for comment made by Reuters by the company.
